Manipulated mesenchymal stem cell therapy in the treatment of Parkinson’s disease
Abstract Mesenchymal stem cell (MSC) therapy has been considered a promising approach for the treatment of Parkinson's disease (PD) for several years. PD is a globally prevalent neurodegenerative disease characterized by the accumulation of Lewy bodies and the loss of dopaminergic neurons, lead...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | Stem Cell Research & Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13287-024-04073-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846112813109477376 |
|---|---|
| author | Seyedeh Toktam Ekrani Mahmoud Mahmoudi Dariush Haghmorad Ramiar Kamal Kheder Alireza Hatami Seyed-Alireza Esmaeili |
| author_facet | Seyedeh Toktam Ekrani Mahmoud Mahmoudi Dariush Haghmorad Ramiar Kamal Kheder Alireza Hatami Seyed-Alireza Esmaeili |
| author_sort | Seyedeh Toktam Ekrani |
| collection | DOAJ |
| description | Abstract Mesenchymal stem cell (MSC) therapy has been considered a promising approach for the treatment of Parkinson's disease (PD) for several years. PD is a globally prevalent neurodegenerative disease characterized by the accumulation of Lewy bodies and the loss of dopaminergic neurons, leading to severe motor and non-motor complications in patients. As current treatments are unable to halt the progression of neuronal loss and dopamine degradation, MSC therapy has emerged as a highly promising strategy for PD treatment. This promise is due to MSCs' unique properties compared to other types of stem cells, including self-renewal, differentiation potential, immune privilege, secretion of neurotrophic factors, ability to improve damaged tissue, modulation of the immune system, and lack of ethical concerns. MSCs have been employed in numerous pre-clinical and clinical studies for PD treatment with promising results. However, certain aspects of their efficacy in treating PD may benefit from various genetic and epigenetic modifications. In this review article, we assess these approaches to improving MSCs for specialized treatment of PD. |
| format | Article |
| id | doaj-art-eb8a09af5ad6469cb57adbaebb37ee7b |
| institution | Kabale University |
| issn | 1757-6512 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Stem Cell Research & Therapy |
| spelling | doaj-art-eb8a09af5ad6469cb57adbaebb37ee7b2024-12-22T12:18:39ZengBMCStem Cell Research & Therapy1757-65122024-12-0115111410.1186/s13287-024-04073-9Manipulated mesenchymal stem cell therapy in the treatment of Parkinson’s diseaseSeyedeh Toktam Ekrani0Mahmoud Mahmoudi1Dariush Haghmorad2Ramiar Kamal Kheder3Alireza Hatami4Seyed-Alireza Esmaeili5Department of Immunology, Semnan University of Medical SciencesImmunology Research Center, Mashhad University of Medical SciencesDepartment of Immunology, Semnan University of Medical SciencesMedical Laboratory Science Department, College of Science, University of RaparinDepartment of Nutrition, Faculty of Medicine, Mashhad University of Medical SciencesImmunology Research Center, Mashhad University of Medical SciencesAbstract Mesenchymal stem cell (MSC) therapy has been considered a promising approach for the treatment of Parkinson's disease (PD) for several years. PD is a globally prevalent neurodegenerative disease characterized by the accumulation of Lewy bodies and the loss of dopaminergic neurons, leading to severe motor and non-motor complications in patients. As current treatments are unable to halt the progression of neuronal loss and dopamine degradation, MSC therapy has emerged as a highly promising strategy for PD treatment. This promise is due to MSCs' unique properties compared to other types of stem cells, including self-renewal, differentiation potential, immune privilege, secretion of neurotrophic factors, ability to improve damaged tissue, modulation of the immune system, and lack of ethical concerns. MSCs have been employed in numerous pre-clinical and clinical studies for PD treatment with promising results. However, certain aspects of their efficacy in treating PD may benefit from various genetic and epigenetic modifications. In this review article, we assess these approaches to improving MSCs for specialized treatment of PD.https://doi.org/10.1186/s13287-024-04073-9Parkinson's diseaseMesenchymal stem cellsMSCs manipulationStem cell therapy |
| spellingShingle | Seyedeh Toktam Ekrani Mahmoud Mahmoudi Dariush Haghmorad Ramiar Kamal Kheder Alireza Hatami Seyed-Alireza Esmaeili Manipulated mesenchymal stem cell therapy in the treatment of Parkinson’s disease Stem Cell Research & Therapy Parkinson's disease Mesenchymal stem cells MSCs manipulation Stem cell therapy |
| title | Manipulated mesenchymal stem cell therapy in the treatment of Parkinson’s disease |
| title_full | Manipulated mesenchymal stem cell therapy in the treatment of Parkinson’s disease |
| title_fullStr | Manipulated mesenchymal stem cell therapy in the treatment of Parkinson’s disease |
| title_full_unstemmed | Manipulated mesenchymal stem cell therapy in the treatment of Parkinson’s disease |
| title_short | Manipulated mesenchymal stem cell therapy in the treatment of Parkinson’s disease |
| title_sort | manipulated mesenchymal stem cell therapy in the treatment of parkinson s disease |
| topic | Parkinson's disease Mesenchymal stem cells MSCs manipulation Stem cell therapy |
| url | https://doi.org/10.1186/s13287-024-04073-9 |
| work_keys_str_mv | AT seyedehtoktamekrani manipulatedmesenchymalstemcelltherapyinthetreatmentofparkinsonsdisease AT mahmoudmahmoudi manipulatedmesenchymalstemcelltherapyinthetreatmentofparkinsonsdisease AT dariushhaghmorad manipulatedmesenchymalstemcelltherapyinthetreatmentofparkinsonsdisease AT ramiarkamalkheder manipulatedmesenchymalstemcelltherapyinthetreatmentofparkinsonsdisease AT alirezahatami manipulatedmesenchymalstemcelltherapyinthetreatmentofparkinsonsdisease AT seyedalirezaesmaeili manipulatedmesenchymalstemcelltherapyinthetreatmentofparkinsonsdisease |